| Literature DB >> 27666194 |
Jérémie Piton1, Caroline S-Y Foo1, Stewart T Cole2.
Abstract
The flavoenzyme DprE1 catalyses a crucial step in arabinan production for cell wall biosynthesis in Mycobacterium tuberculosis and is a highly vulnerable drug target. It was first discovered using benzothiazinones (BTZ): exquisitely potent bactericidal agents that are being developed as drugs to treat tuberculosis. Subsequently, many compounds with diverse scaffolds were found to act as either covalent or noncovalent DprE1 inhibitors. Covalent inhibitors, like the BTZ, are all nitroaromatic compounds that serve as suicide substrates after DprE1-mediated nitroreduction. Here, we describe how high-resolution structures of DprE1, alone and in complex with various ligands, explain enzyme activity and inhibition.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27666194 DOI: 10.1016/j.drudis.2016.09.014
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851